Shanghai Medicilon Inc. (SHA:688202)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Drug Discovery and Pharmaceutical Research	573.03M	495.07M	631.80M	735.24M	612.97M
Drug Discovery and Pharmaceutical Research Growth	15.75%	-21.64%	-14.07%	19.95%	72.68%
Preclinical Study	589.91M	542.21M	733.80M	923.63M	553.53M
Preclinical Study Growth	8.80%	-26.11%	-20.55%	66.86%	78.19%
Total	1.16B	1.04B	1.37B	1.66B	1.17B
Total Growth	12.11%	-24.04%	-17.68%	42.21%	75.25%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
China	614.58M	-	-	-	-
Overseas	548.36M	-	-	-	-
Total	1.16B	-	-	-	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 19, 2026

Data Sources Report a data error